

**Resolution 1**  
**of the Ordinary General Meeting of Shareholders**  
**of Ryvu Therapeutics S.A., headquartered in Krakow, Poland**  
**of June 25, 2026**  
**on the election of the chairman**

The Annual General Meeting of Ryvu Therapeutics S.A., headquartered in Krakow, Poland, resolves as follows:

§ 1

\_\_\_\_\_ is hereby appointed as the Chairperson of the General Meeting of Shareholders.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 1:  
The resolution is of a technical nature. The necessity to elect the Chairperson of the General Meeting after the opening of the General Meeting results from Article 409 § 1 of the Commercial Companies Code.

**Resolution 2**  
**of the Ordinary General Meeting of Shareholders**  
**of Ryvu Therapeutics S.A., headquartered in Krakow, Poland**  
**of June 25, 2026**  
**on approval of the agenda**

The Annual General Meeting of Ryvu Therapeutics S.A., headquartered in Krakow, Poland, resolves as follows:

§ 1

The Annual General Meeting of Ryvu Therapeutics S.A., headquartered in Cracow, hereby approves the following agenda:

1. Opening of the meeting.
2. Election of the Chairperson of the Meeting.
3. Determination by the Chairperson of the correctness of the Assembly's convening and its ability to adopt resolutions.
4. Adoption of the agenda.
5. Assessment of:
  - 1) the Management Board's report on the Company's activities for the 2025 fiscal year.
  - 2) the Company's financial statements for the 2025 fiscal year.
  - 3) the Supervisory Board's report for the 2025 fiscal year including the evaluation of the Company's financial statements for the 2025 fiscal year, the Management Board's report on the Company's activities for the 2025 fiscal year and the Management Board's proposal to cover the loss for the 2025 fiscal year.
6. Adoption of a resolution on:
  - 1) approval of the Management Board's report on the Company's activities for the 2025 fiscal year.
  - 2) approval of the Company's financial statements for the 2025 fiscal year.
  - 3) covering the loss for the 2025 fiscal year.
7. Adoption of resolutions on granting discharge to members of the Company's Management Board and Supervisory Board.
8. Adoption of a resolution on the opinion regarding the report on the remuneration of the members of the Management Board and the Supervisory Board for the 2025 fiscal year.
9. Adoption of resolutions on the appointment of members of the Supervisory Board for the new term.
10. Adoption of resolution on remuneration of Supervisory Board.
11. Adoption of a resolution on consent to the amendment of the Supervisory Board Rules.

12. Adoption of a resolution regarding amendment to the Articles of Association.
13. Closing of the meeting.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Board of Directors to the draft resolution No. 2:

The resolution is technical in nature and is required on basis of Article 404 of the Commercial Companies Code.

**Resolution 3  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026**

**on approval of the Management Board's report on the activities of Ryvu Therapeutics S.A.**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Cracow (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(1) of the Commercial Companies Code, resolves as follows:

§ 1

After consideration, the report of the Management Board on the Company's activities for fiscal year 2025 covering the period 01.01.2025-31.12.2025 is approved.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft Resolution No. 3:

The legal basis for adopting the resolution derives from Article 395 § 2(1) of the Commercial Companies Code.

**Resolution 4  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026**  
**on approval of the financial statements of Ryvu Therapeutics S.A.**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(1) of the Commercial Companies Code, resolves as follows:

§ 1

After consideration, the Company's financial statements for fiscal year 2025 covering the period 01.01.2025-31.12.2025 are approved.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft Resolution No. 4:

The legal basis for adopting the resolution derives from Article 395 § 2(1) of the Commercial Companies Code.

**Resolution 5  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026**  
**on covering the loss for the financial year 2025**

The Ordinary General Meeting of Ryvu Therapeutics S.A., with its seat in Cracow (the "Company"), acting pursuant to Article 395 § 2(2) of the Commercial Companies Code, resolves as follows:

§ 1

Cover the Company's net loss for 2025, covering the period 01.01.2025-31.12.2025, amounting to PLN 101,228,930.00 with profits from future years.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft Resolution No. 5:

The legal basis for the adoption of the resolution derives from Article 395 § 2(2) of the Commercial Companies Code. The motion to cover the loss for 2025 with profits from future years was submitted by the Company's Management Board and then received a positive opinion from the Company's Supervisory Board. Generating losses at this stage of the Company's portfolio development is not unusual, considering the scope of the Company's business, based on development of innovative drugs.

**Resolution 6  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Cracow (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

The President of the Company's Management Board, Mr. Paweł Przewięźlikowski, is hereby granted discharge for the performance of his duties in the 2025 fiscal year from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 6: The resolution is a typical resolution adopted by the Ordinary General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 7  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Cracow (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

The Vice President of the Company's Management Board, Mr. Krzysztof Brzózka, is hereby granted discharge for the performance of his duties in the 2025 fiscal year from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 7: The resolution is a typical resolution adopted by the Ordinary General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 8  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026**

**on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

The Member of the Company's Management Board, Mr. Kamil Sitarz, is hereby granted discharge for the performance of his duties in the 2025 fiscal year for the period from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 8: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 9  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

The Member of the Company's Management Board, Mr. Vatnak Vat-Ho, is hereby granted discharge for the performance of his duties in the 2025 fiscal year for the period from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 9: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 10  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

Discharge is granted to Mr. Franz Hendrik Nogai, a member of the Company's Management Board, for the performance of his duties in the 2025 fiscal year from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 10: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 11  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

Discharge is granted to Mrs. Justyna Żółtek, a member of the Company's Management Board, for the performance of his duties in the 2025 fiscal year from June 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 11: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 12  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

The Chairman of the Company's Supervisory Board, Mr. Piotr Romanowski, is hereby granted discharge for the performance of his duties in the 2025 fiscal year from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 12: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 13  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

The Vice-Chairman of the Company's Supervisory Board, Mr. Tadeusz Wesolowski, is hereby granted discharge for the performance of his duties in the 2025 fiscal year from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 13: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 14  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026**

**on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Cracow (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

Member of the Company's Supervisory Board, Mr. Rafal Chwast, is hereby granted discharge for the performance of his duties in the 2025 fiscal year from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 14: The resolution is a typical resolution adopted by the Ordinary General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 15  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Cracow (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

Member of the Company's Supervisory Board, Mr. Axel Glasmacher, is hereby granted discharge for the performance of his duties in the 2025 fiscal year from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 15: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 16  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

§ 1

Member of the Company's Supervisory Board, Mr. Thomas Turalski, is hereby granted discharge for the performance of his duties in the 2025 fiscal year for the period from January 1 to December 31, 2025.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 16: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

**Resolution 17  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026**

### **on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

#### **§ 1**

Member of the Company's Supervisory Board, Mr. Scott Fields, is hereby granted discharge for the performance of his duties in the 2025 fiscal year for the period from January 1 to December 31, 2025.

#### **§ 2**

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 17: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

### **Resolution 18 of the Ordinary General Meeting of Shareholders of Ryvu Therapeutics S.A., headquartered in Krakow, Poland of June 25, 2026 on the granting of discharge**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków, Poland (the "Company"), acting pursuant to Article 393(1) and Article 395 § 2(3) of the Commercial Companies Code, resolves as follows:

#### **§ 1**

Member of the Company's Supervisory Board, Mr. Peter Smith, is hereby granted discharge for the performance of his duties in the 2025 fiscal year for the period from January 1 to December 31, 2025.

#### **§ 2**

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to draft resolution No. 18: The resolution is a typical resolution adopted by the Annual General Meeting. The necessity of the resolution is based on Article 395 § 2 item 3 of the Commercial Companies Code.

### **Resolution 19 of the Ordinary General Meeting of Shareholders of Ryvu Therapeutics S.A., headquartered in Krakow, Poland of June 25, 2026 on expressing the opinion on the Supervisory Board Report on Remuneration of Management Board and Supervisory Board of Ryvu Therapeutics S.A. for 2025**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków (the "Company"), acting pursuant to Article 90g (6) of the Act of July 29, 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies (Journal of Laws of 2025, item 592), resolves as follows:

#### **§ 1**

The Ordinary General Meeting resolves to give a positive opinion on Supervisory Board Report on Remuneration of Management Board and Supervisory Board of Ryvu Therapeutics S.A. for 2025.

#### **§ 2**

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 19: The necessity to adopt the resolution arises from Article 395 § 21 of the Commercial Companies Code in connection with Article

90g (6) of the Act of July 29, 2005 on Public Offering and Conditions Governing the Introduction of Financial Instruments to Organized Trading and Public Companies.

**Resolution 20**  
**of the Ordinary General Meeting of Shareholders**  
**of Ryvu Therapeutics S.A., headquartered in Krakow, Poland**  
**of June 25, 2026**  
**on the appointment of member of the Supervisory Board**

The Ordinary General Meeting of Ryvu Therapeutics S.A. with its registered office in Kraków (“the Company”), acting pursuant to 385 § 1 of Commercial Companies Code and § 19(1)(j) of the Company’s Articles of Association, hereby resolves as follows:

§ 1

\_\_\_\_\_ is appointed to serve as a member of the Company’s Supervisory Board.

§ 2

This resolution shall enter into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 20: The resolution is required due to the expiration of the terms of office of the current members of the Supervisory Board

**Resolution 21**  
**of the Ordinary General Meeting of Shareholders**  
**of Ryvu Therapeutics S.A., headquartered in Krakow, Poland**  
**of June 25, 2026**  
**on the appointment of member of the Supervisory Board**

The Ordinary General Meeting of Ryvu Therapeutics S.A. with its registered office in Kraków (“the Company”), acting pursuant to 385 § 1 of Commercial Companies Code and § 19(1)(j) of the Company’s Articles of Association, hereby resolves as follows:

§ 1

\_\_\_\_\_ is appointed to serve as a member of the Company’s Supervisory Board.

§ 2

This resolution shall enter into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 21: The resolution is required due to the expiration of the terms of office of the current members of the Supervisory Board

**Resolution 22**  
**of the Ordinary General Meeting of Shareholders**  
**of Ryvu Therapeutics S.A., headquartered in Krakow, Poland**  
**of June 25, 2026**  
**on the appointment of member of the Supervisory Board**

The Ordinary General Meeting of Ryvu Therapeutics S.A. with its registered office in Kraków (“the Company”), acting pursuant to 385 § 1 of Commercial Companies Code and § 19(1)(j) of the Company’s Articles of Association, hereby resolves as follows:

§ 1

\_\_\_\_\_ is appointed to serve as a member of the Company’s Supervisory Board.

§ 2

This resolution shall enter into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 22: The resolution is required due to the expiration of the terms of office of the current members of the Supervisory Board

**Resolution 23**

**of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the appointment of member of the Supervisory Board**

The Ordinary General Meeting of Ryvu Therapeutics S.A. with its registered office in Kraków (“the Company”), acting pursuant to 385 § 1 of Commercial Companies Code and § 19(1)(j) of the Company’s Articles of Association, hereby resolves as follows:

§ 1

\_\_\_\_\_ is appointed to serve as a member of the Company’s Supervisory Board.

§ 2

This resolution shall enter into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 23: The resolution is required due to the expiration of the terms of office of the current members of the Supervisory Board

**Resolution 24  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on the appointment of member of the Supervisory Board**

The Ordinary General Meeting of Ryvu Therapeutics S.A. with its registered office in Kraków (“the Company”), acting pursuant to 385 § 1 of Commercial Companies Code and § 19(1)(j) of the Company’s Articles of Association, hereby resolves as follows:

§ 1

\_\_\_\_\_ is appointed to serve as a member of the Company’s Supervisory Board.

§ 2

This resolution shall enter into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 24: The resolution is required due to the expiration of the terms of office of the current members of the Supervisory Board

**Resolution 25  
of the Ordinary General Meeting of Shareholders  
of Ryvu Therapeutics S.A., headquartered in Krakow, Poland  
of June 25, 2026  
on Remuneration of Supervisory Board**

The Ordinary General Meeting of Ryvu Therapeutics S.A. with its registered office in Kraków (the “Company”), acting pursuant to Article 392 § 1 of the Polish Commercial Companies Code and § 19 section 1 letter l) of the Company’s Articles of Association, hereby resolves as follows:

§ 1

The remuneration of the members of the Supervisory Board of the Company for the new term of office is hereby determined at EUR \_\_\_\_\_ gross per month.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 25: Determination of the remuneration of the members of the Supervisory Board for the new term of office falls within the competence of the General Meeting pursuant to Article 392 § 1 of the Polish Commercial Companies Code and § 19 section 1 letter l) of the Company’s Articles of Association.

**Resolution 26**  
**of the Ordinary General Meeting of Shareholders**  
**of Ryvu Therapeutics S.A., headquartered in Krakow, Poland**  
**of June 25, 2026**  
**on consent to the amendment of the Supervisory Board Rules**

The Ordinary General Meeting of Ryvu Therapeutics S.A., headquartered in Kraków (the "Company"), acting pursuant to to § 21 of the Company's Articles of Association, resolves as follows:

§ 1

Consent is hereby granted to the amendment of the Supervisory Board Rules adopted pursuant to the Resolution of the Supervisory Board No.10/05/2026 dated May 22, 2026, attached to this Resolution.

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 26: The resolution is required in order to approve the amended Supervisory Board Rules in accordance with § 21 of the Company's Articles of Association.

**Resolution 27**  
**of the Ordinary General Meeting of Shareholders**  
**of Ryvu Therapeutics S.A., headquartered in Krakow, Poland**  
**of June 25, 2026**  
**regarding amendment to the Articles of Association.**

The Ordinary General Meeting of Ryvu Therapeutics S.A. with its registered office in Kraków ("the Company"), acting pursuant to § 19(1)(h) of the Company's Articles of Association, hereby resolves as follows:

§ 1

Section 5(1) of the Company's Articles of Association shall be amended and restated as follows:

§ 5

*The Company's business activities, according to the Polish Classification of Activities (PKD), shall include:*

- 1) *Cultivation of spice, aromatic and medicinal plants used in the production of medicines and pharmaceutical products (PKD 01.28.Z),*
- 2) *Cultivation of other perennial crops (PKD 01.29.Z),*
- 3) *Plant propagation (PKD 01.30.Z),*
- 4) *Raising and breeding of other animals (PKD 01.48.Z),*
- 5) *Support activities for crop production (PKD 01.61.Z),*
- 6) *Support activities for animal production (PKD 01.62.Z),*
- 7) *Post-harvest crop activities and seed processing for propagation purposes (PKD 01.63.Z),*
- 8) *Manufacture of other food products, excluding dietary supplements, meat substitutes, plant-based substitutes for eggs, dairy and other milk products, not elsewhere classified (PKD 10.89.D),*
- 9) *Manufacture of other basic inorganic chemicals (PKD 20.13.Z),*
- 10) *Manufacture of other basic organic chemicals (PKD 20.14.Z),*
- 11) *Manufacture of disinfectants (PKD 20.20.B),*
- 12) *Manufacture of other agrochemical products (PKD 20.20.C),*
- 13) *Manufacture of soap and detergents, cleaning and polishing preparations (PKD 20.41.Z),*
- 14) *Manufacture of perfumes and toilet preparations (PKD 20.42.Z),*
- 15) *Manufacture of other chemical products not elsewhere classified (PKD 20.59.Z),*
- 16) *Manufacture of basic pharmaceutical products (PKD 21.10.Z),*
- 17) *Manufacture of pharmaceutical preparations and other pharmaceutical products (PKD 21.20.Z),*
- 18) *Manufacture of computers and peripheral equipment (PKD 26.20.Z),*
- 19) *Manufacture of other medical devices, instruments and products (PKD 32.50.B),*
- 20) *Collection of non-hazardous waste (PKD 38.11.Z),*
- 21) *Collection of hazardous waste (PKD 38.12.Z),*

- 22) *Waste disposal (PKD 38.32.Z),*
- 23) *Remediation activities and other waste management services (PKD 39.00.Z),*
- 24) *Activities of agents involved in non-specialised wholesale trade (PKD 46.19.Z),*
- 25) *Wholesale of information and communication technology equipment (PKD 46.50.Z),*
- 26) *Other wholesale of chemical products (PKD 46.85.B),*
- 27) *Non-specialised wholesale trade (PKD 46.90.Z),*
- 28) *Retail sale of other new goods (PKD 47.78.Z),*
- 29) *Freight transport by road (PKD 49.41.Z),*
- 30) *Warehousing and storage of other goods (PKD 52.10.B),*
- 31) *Other service activities incidental to land transportation (PKD 52.21.B),*
- 32) *Other publishing activities, excluding software publishing (PKD 58.19.Z),*
- 33) *Other software publishing activities (PKD 58.29.Z),*
- 34) *Other software development activities (PKD 62.10.B),*
- 35) *Other information technology and computer service activities relating to computing infrastructure, data processing, website hosting and related activities (PKD 63.10.D),*
- 36) *Other content distribution activities (PKD 63.39.Z),*
- 37) *News agency activities (PKD 63.91.Z),*
- 38) *Other information service activities (PKD 63.92.Z),*
- 39) *Buying and selling of own real estate (PKD 68.11.Z),*
- 40) *Renting and operating of own or leased real estate (PKD 68.20.Z),*
- 41) *Real estate brokerage activities (PKD 68.31.Z),*
- 42) *Management of real estate on a fee or contract basis (PKD 68.32.B),*
- 43) *Business and other management consultancy activities (PKD 70.20.Z PKD),*
- 44) *Other public relations and communication activities (PKD 73.30.B),*
- 45) *Testing and analysis related to food quality (PKD 71.20.A),*
- 46) *Other technical testing and analysis (PKD 71.20.C),*
- 47) *Research and experimental development in natural sciences and engineering (PKD 72.10.Z),*
- 48) *Advertising agencies activities (PKD 73.11.Z),*
- 49) *Renting and leasing of office machinery and equipment, including computers (PKD 77.33.Z),*
- 50) *Renting and leasing of other machinery, equipment and tangible goods not elsewhere classified (PKD 77.39.Z),*
- 51) *Leasing of intellectual property and similar products, except copyrighted works (PKD 77.40.B),*
- 52) *Activities of employment placement agencies and personnel recruitment (PKD 78.10.Z),*
- 53) *Office administrative and support activities (PKD 82.10.Z),*
- 54) *Other business support service activities not elsewhere classified (PKD 82.99.Z),*
- 55) *Other education not elsewhere classified (PKD 85.59.B),*
- 56) *Educational support activities (PKD 85.60.Z),*
- 57) *Paramedical activities (PKD 86.90.D),*
- 58) *Other human health activities not elsewhere classified (PKD 86.90.E).*

§ 2

The resolution comes into force upon its adoption.

Justification of the Company's Management Board to the draft resolution No. 27: It is required to adopt a resolution regarding an amendment to the Company's Articles of Association in connection with the update of the current PKD codes.